Delivery Order SPE2DB22D1202-SPE2DB25FVJW8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $1,100.64. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply transaction under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 20 mg capsules (100 count) with a contract ceiling value of $2,229.50. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 2, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100-count units) on August 15, 2025, with a ceiling value of $4,198.84. This firm fixed-price delivery order is set to be completed by August 18, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) with a ceiling value of $7,938.11. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competition. The contract is scheduled for ultimate completion on August 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) under a firm fixed-price contract valued at $14,662.29. This non-competitive delivery order is set to be completed by August 29, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 30 mg capsules (100-count) with a contract value of $2,117.56 and completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,143.98. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive award to the prime contractor. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVJW8Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 50 mg capsules (100 count units) with a ceiling value of $1,441.35. This is a firm fixed price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive, non-set-aside award. The contract is performed from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and federal healthcare solutions provider, AmerisourceBergen supplies a broad range of medications and medical commodities to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Vyvanse, a stimulant medication, represents the type of specialized pharmaceutical products distributed through this framework to meet military and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 8/29/25 |